NOVAVAX INC Payments to Acquire Debt Securities, Available-for-sale
NOVAVAX INC (NVAX) reported Payments to Acquire Debt Securities, Available-for-sale of $295.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- NOVAVAX INC payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $81.69M.
- NOVAVAX INC payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $214.13M, a 86.65% increase year-over-year.
- NOVAVAX INC payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $235.01M, a 227.85% increase year-over-year.
- NOVAVAX INC payments to acquire debt securities, available-for-sale for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month |
|---|---|---|---|
| 2026-06-30 | $81.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $295.82M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $214.13M 10-Q · filed 2026-05-06 | ||
| 2025-09-30 | $235.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $235.01M derived: sum of 2 quarters · filed 2026-08-06 | $349.74M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $114.72M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $114.72M 10-Q · filed 2026-05-06 | ||
| 2024-09-30 | $71.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $441.26M derived: sum of 2 quarters · filed 2025-11-06 | $441.26M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $369.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $369.58M 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |